{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:11:27Z","timestamp":1779451887275,"version":"3.53.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clbc.2025.12.012","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T15:53:15Z","timestamp":1767455595000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practical Considerations for the Use of Antiemetics in Pregnant Patients With Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1837-716X","authenticated-orcid":false,"given":"Arianne","family":"Duong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane","family":"Fritzsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1534-0062","authenticated-orcid":false,"given":"Amy Ly","family":"Indorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2025.12.012_bib0001","first-page":"131","article-title":"Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting","volume":"19","author":"Burke","year":"2011","journal-title":"Supp Care Cancer"},{"issue":"6","key":"10.1016\/j.clbc.2025.12.012_bib0002","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.012_bib0003","doi-asserted-by":"crossref","first-page":"28","DOI":"10.14740\/wjon1177","article-title":"Cancer during pregnancy: the oncologist overview","volume":"10","author":"Hepner","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.clbc.2025.12.012_bib0004","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.012_bib0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-3016.2006.00723.x","article-title":"Nausea and vomiting in pregnancy: maternal characteristics and risk factors","volume":"20","author":"Louik","year":"2006","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.012_bib0006","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/AOG.0000000000002604","article-title":"ACOG practice bulletin 189: nausea and vomiting of pregnancy","volume":"131","author":"Erick","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.012_bib0007","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1067\/mob.2002.122592","article-title":"Nausea and vomiting of pregnancy: an obstetric syndrome","volume":"186","author":"Goodwin","year":"2002","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.clbc.2025.12.012_bib0008","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.3390\/cancers12123616","article-title":"Update on the management of breast cancer during pregnancy","volume":"12","author":"Poggio","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2025.12.012_bib0009","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.breast.2017.07.008","article-title":"Epidemiology and pathophysiology of pregnancy-associated breast cancer: a review","volume":"35","author":"Ruiz","year":"2017","journal-title":"Breast"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.012_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.39934","article-title":"Treatments during pregnancy targeting erbb2 and outcomes of pregnant individuals and newborns","volume":"6","author":"Gougis","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.012_bib0011","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3390\/pharmaceutics14102080","article-title":"Cancer treatment and immunotherapy during pregnancy","volume":"14","author":"Koutras","year":"2022","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.clbc.2025.12.012_bib0012","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamaoncol.2015.2413","article-title":"Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients","volume":"1","author":"Loibl","year":"2015","journal-title":"JAMA oncology"},{"key":"10.1016\/j.clbc.2025.12.012_bib0013","article-title":"Pharmacokinetic data in pregnancy: a review of available literature data and important considerations in collecting clinical data","volume":"9","author":"Coppola","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.012_bib0014","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajog.2021.02.002","article-title":"Obstetrical, fetal, and lactation pharmacology: a crisis that can no longer be ignored","volume":"225","author":"Caritis","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.clbc.2025.12.012_bib0015","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1517\/17425255.2015.1055247","article-title":"Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developments","volume":"11","author":"Bell","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"10.1016\/j.clbc.2025.12.012_bib0016","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/AOG.0000000000000242","article-title":"Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial","volume":"123","author":"Abas","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.012_bib0017","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/AOG.0000000000000479","article-title":"Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial","volume":"124","author":"Oliveira","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.012_bib0018","first-page":"443","article-title":"Ondansetron versus metoclopramide in the prevention of chemotherapy-induced nausea and vomiting-a metaanalysis","volume":"1","author":"Rusthoven","year":"1992","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clbc.2025.12.012_bib0019","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.reprotox.2014.10.017","article-title":"Use of ondansetron during pregnancy and congenital malformations in the infant","volume":"50","author":"Danielsson","year":"2014","journal-title":"Reprod Toxicol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.012_bib0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/bdra.22865","article-title":"Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects","volume":"94","author":"Anderka","year":"2012","journal-title":"Birth Defects Res Clin Mol Teratol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.012_bib0021","first-page":"113","article-title":"Ondansetron compared with granisetron in the prophylaxis of cisplatin-lnduced acute emesis: a multicentre double-blind, randomised, parallel-group study","volume":"51","author":"Ruff","year":"1994","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.012_bib0022","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/A:1008235023749","article-title":"Management of cancer in pregnancy: a case of Ewing's sarcoma of the pelvis in the third trimester","volume":"10","author":"Merimsky","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2025.12.012_bib0023","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejogrb.2019.11.033","article-title":"The safety of early pregnancy exposure to granisetron","volume":"245","author":"Shapira","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.clbc.2025.12.012_bib0024","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s13224-015-0709-6","article-title":"Comparison of efficacy of granisetron and promethazine in control of hyperemesis gravidarum","volume":"66","author":"Aleyasin","year":"2016","journal-title":"J Obstet Gynaecol India"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.012_bib0025","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","article-title":"Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron","volume":"14","author":"Gralla","year":"2003","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.012_bib0026","doi-asserted-by":"crossref","first-page":"93.e1","DOI":"10.1016\/j.ajog.2016.01.163","article-title":"Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy","volume":"215","author":"Caritis","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clbc.2025.12.012_bib0027","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.reprotox.2015.02.011","article-title":"Evaluating the potential effect on fetal tissue after exposure to granisetron during pregnancy","volume":"53","author":"Smith","year":"2015","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.clbc.2025.12.012_bib0028","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2013.10.008","article-title":"The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting","volume":"722","author":"Chu","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.012_bib0029","doi-asserted-by":"crossref","first-page":"456","DOI":"10.6004\/jnccn.2012.0047","article-title":"Antiemesis","volume":"10","author":"Ettinger","year":"2012","journal-title":"J Natl Comp Canc Netw"},{"key":"10.1016\/j.clbc.2025.12.012_bib0030","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta","year":"2012","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.012_bib0031","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/annonc\/mdl347","article-title":"Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis","volume":"18","author":"Grunberg","year":"2007","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.clbc.2025.12.012_bib0032","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/jama.2016.14337","article-title":"Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review","volume":"316","author":"McParlin","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.012_bib0033","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/OGX.0000000000000654","article-title":"The management of nausea and vomiting of pregnancy: synthesis of national guidelines","volume":"74","author":"Tsakiridis","year":"2019","journal-title":"Obstet Gynecol Surv"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.012_bib0034","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4274\/jcrpe.v3i3.31","article-title":"Fetal adrenal suppression due to maternal corticosteroid use: case report","volume":"3","author":"Kurto\u011flu","year":"2011","journal-title":"J Clin Res Ped Endocrinol"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.012_bib0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.rdc.2017.04.013","article-title":"A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes","volume":"43","author":"Bandoli","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"issue":"12","key":"10.1016\/j.clbc.2025.12.012_bib0036","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1517\/17425250903304049","article-title":"Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues","volume":"5","author":"Myllynen","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.012_bib0037","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.placenta.2005.12.010","article-title":"Metabolism of synthetic steroids by the human placenta","volume":"28","author":"Murphy","year":"2007","journal-title":"Placenta"},{"key":"10.1016\/j.clbc.2025.12.012_bib0038","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokin"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.012_bib0039","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(77)90233-9","article-title":"Potency and duration of action of glucocorticoids: effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function","volume":"63","author":"Meikle","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.clbc.2025.12.012_bib0040","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejphar.2013.08.048","article-title":"Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting","volume":"722","author":"Navari","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.012_bib0041","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study","volume":"47","author":"Mizukami","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"10.1016\/j.clbc.2025.12.012_bib0042","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1586\/ern.09.54","article-title":"Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?","volume":"9","author":"Citrome","year":"2009","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.012_bib0043","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(23)00628-9","volume":"25","author":"Bajpai","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.012_bib0044","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cpt.770","article-title":"Treatment with antipsychotics in pregnancy: changes in drug disposition","volume":"103","author":"Westin","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.clbc.2025.12.012_bib0045","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1176\/appi.ajp.2007.06111886","article-title":"Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes","volume":"164","author":"Newport","year":"2007","journal-title":"Am J Psych"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.012_bib0046","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/01.pra.0000351878.45260.94","article-title":"Use and safety of antipsychotic drugs during pregnancy","volume":"15","author":"Einarson","year":"2009","journal-title":"J Psychiatr Pract"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.012_bib0047","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1756-9966-28-131","article-title":"Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting","volume":"28","author":"Tan","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clbc.2025.12.012_bib0048","unstructured":"FDA. FDA drug safety communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Available at: http:\/\/www.fda.gov Accessed: February 22, 2011"},{"key":"10.1016\/j.clbc.2025.12.012_bib0049","first-page":"204","article-title":"Corticosteroids, dopamine antagonists and other drugs","volume":"6","author":"Herrstedt","year":"1998","journal-title":"Supp Care Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.012_bib0050","doi-asserted-by":"crossref","first-page":"P85","DOI":"10.1016\/j.clpt.2003.11.324","article-title":"In-vitro characterization of the metabolism of prochlorperazine","volume":"75","author":"Collins","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.012_bib0051","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0009-9236(97)90118-1","article-title":"Induction of CYP2D6 in pregnancy","volume":"62","author":"Wadelius","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.012_bib0052","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10928-020-09711-2","article-title":"Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy","volume":"47","author":"Abduljalil","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.012_bib0053","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/bja\/83.5.761","article-title":"Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies","volume":"83","author":"Henzi","year":"1999","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.clbc.2025.12.012_bib0054","first-page":"829","article-title":"Review of a new gastrointestinal drug\u2013metoclopramide","volume":"38","author":"Ponte","year":"1981","journal-title":"Am J Hosp Pharm"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.012_bib0055","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2125.2000.00127.x","article-title":"Birth outcome following maternal use of metoclopramide","volume":"49","author":"S\u00f8rensen","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clbc.2025.12.012_bib0056","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fphar.2019.00931","article-title":"Metoclopramide-induced acute dystonic reactions may be associated with the CYP2D6 poor metabolizer status and pregnancy-related hormonal changes","volume":"10","author":"Chua","year":"2019","journal-title":"Front Pharmacol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925003581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925003581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:46:26Z","timestamp":1779450386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925003581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1526820925003581"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.12.012","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical Considerations for the Use of Antiemetics in Pregnant Patients With Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}